Gene Typo is a Double Whammy that Creates Sickening Sticky Mucus PDF Print E-mail

An imbalance of salt and water in patients with cystic fibrosis makes their lungs clog up with sticky mucus that is prone to infection. The cause of the offending imbalance is a well-known genetic error, one that blocks the molecular expressway for tiny chloride ions to move across the surface of the lungs.

But how does that same gene mutation upset a parallel roadway controlling the flow of the other component of salt, sodium ions? Now, researchers at NC TraCS have found the answer, demonstrating that the gene mutated in cystic fibrosis not only controls traffic on the chloride highway, but also keeps the sodium highway from being overused.

The finding suggests that the infamous mutation – in a gene called CFTR – is a double whammy, affecting the flow of two different ions that are important to keep the mucus on the surfaces of the airways hydrated. Clarifying this link between the genetic defect and the thick sticky mucus in cystic fibrosis lungs could help researchers develop better therapies.

“It is very important to calm down this sodium channel when it is overactive before it leads to dehydration of the mucus in patient airways,” said Martina Gentzsch, Ph.D., assistant professor of cell and developmental biology at UNC, who co-authored the study with Ric Boucher, M.D., PI extender at NC TraCS and director of the Cystic Fibrosis/Pulmonary Research and Treatment Center. “If we can understand the mechanism of how CFTR does that, it might give us a new approach to treat the disease.”

Cystic fibrosis is one of the most common genetic diseases in whites, affecting approximately 1 in 3500 births in the United States. It is caused by a defect in the gene that codes for a protein called cystic fibrosis transmembrane conductance regulator or CFTR. Cystic fibrosis patients with the most severe disease have very little of the CFTR protein, and this affects the way chloride ions move across many tissues in the body. A number of scientists have hypothesized that CFTR also controls the movement of other ions, such as through the epithelial sodium channel or ENaC.

This channel has been shown to be overactive in transporting sodium ions in the airways of cystic fibrosis patients, so Gentzsch and her colleagues set out to determine why. First, they looked at the effects of the CFTR gene on the sodium channel in xenopus oocytes, commonly known as frog eggs. They found that when the CFTR gene was intact, the sodium channel was kept in check.

The researchers followed up with a number of biochemical and electrophysiological experiments and showed that the chloride channel and the sodium channels interact. Gentzsch and her colleagues also confirmed their results in human primary airway epithelial cells from healthy volunteers and patients with cystic fibrosis, showing that the sodium channel was in fact more active when there was no functional CFTR.

Now that they know that the chloride channel can actually influence the function of the sodium channel, Gentzsch is trying to find out how.

“We don’t know if it is doing this by basically acting like a roadblock, physically interfering with the proteases that can activate the channel, or if it is doing it by some other more indirect means,” said Gentzsch, whose results were published October 15 in the Journal of Biological Chemistry. “That is what we are investigating at the moment, so there are a lot more questions to be answered.”

This article originally appeared on news.unchealthcare.org

By Marla Broadfoot
 

Carolina KickStart News & Reminders

Commercialization Award Recipients
Rounds 1 and 2:
Enci Therapeutics
G-Zero Therapeutics
Capture Pharmaceuticals
Hibernaid
Synereca Pharmaceuticals
X-in8 Biologicals Corporation

Rounds 4, 5 & 6:
Cell Microsystems
Ironwood Material Science
Cortical Metrics
Novolipid
LotusBioEFx
NeuroGate
Qualiber
Funding Deadlines
NSF STTR
December 2, 2011

HHS/NIH SBIR/STTR
December 5, 2011

Company Inception Loan (CIL)
NC Biotechnology Center

Deadline Rolling

The North Carolina Clinical and Translational Sciences (NC TraCS) Institute is one of 60 medical research institutions working together as a national consortium to improve the way biomedical research is conducted across the country. The consortium, funded through Clinical and Translational Science Awards (CTSA), shares a common vision to reduce the time it takes for laboratory discoveries to become treatments for patients, and to engage communities in clinical research efforts. It also is fulfilling the critical need to train a new generation of clinical researchers. The CTSA program is led by the National Center for Research Resources, part of the National Institutes of Health. For more information about NC TraCS programs and services, and the UNC-CH CTSA, call us at 919.966.6022, email us at nctracs@unc.edu, or visit us online at tracs.unc.edu